RNAZTranscode Therapeutics, Inc.
- Market cap
- $29.97M
- as of 2026-10-23
- Latest close
- $1.77
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2023-10-02
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Fitzgerald Thomas AChief Financial Officer | Sep 9 | Sep 11 | A · derivative | 185,000 | $1.78 | $329,300 | 185,000 | No | Form 4 |
| CK Life Sciences Intl (Holdings) Inc | Aug 3 | Aug 5 | C | 11,813,859 | not reported | not reported | 12,113,899 | No | Form 4 |
| CK Life Sciences Intl (Holdings) Inc | Aug 3 | Aug 5 | C | 2,020,582 | not reported | not reported | 14,134,481 | No | Form 4 |
| CK Life Sciences Intl (Holdings) Inc | Aug 3 | Aug 5 | C · derivative | 1,181.39 | $0.00 | $0 | not reported | No | Form 4 |
| CK Life Sciences Intl (Holdings) Inc | Aug 3 | Aug 5 | C · derivative | 202.06 | $0.00 | $0 | not reported | No | Form 4 |
| Calais Philippe | Jun 14, 2024 | Jun 18, 2024 | A · derivative | 70,000 | $1.20 | $84,000 | 70,000 | No | Form 4 |
| Fitzgerald Thomas AInterim CEO, CFO | Jun 14, 2024 | Jun 18, 2024 | A · derivative | 650,000 | $1.20 | $780,000 | 650,000 | No | Form 4 |
| Manting Erik | Jun 14, 2024 | Jun 18, 2024 | A · derivative | 70,000 | $1.20 | $84,000 | 70,000 | No | Form 4 |
| Marquet Magda | Jun 14, 2024 | Jun 18, 2024 | A · derivative | 70,000 | $1.20 | $84,000 | 70,000 | No | Form 4 |
| Dudley Robert MichaelChief Executive Officer | Sep 28, 2023 | Oct 2, 2023 | P | 98,000 | $0.51 | Purchase +$49,980 | 180,262 | No | Form 4 |
| Fitzgerald Thomas AChief Financial Officer | Sep 28, 2023 | Oct 2, 2023 | P | 49,350 | $0.51 | Purchase +$25,169 | 56,318 | No | Form 4 |